ConductScience.org, home

Paper42974396PubMed

Identification of B-cell maturation antigen (BCMA)-targeting peptides and selective drug delivery to multiple myeloma using peptide-targeted DM1 prodrug-loaded nanoparticles.

Hwang G and 4 others. Nanoscale Adv, 2026.

Cite this record

ConductScience Library. Identification of B-cell maturation antigen (BCMA)-targeting peptides and selective drug delivery to multiple myeloma using peptide-targeted DM1 prodrug-loaded nanoparticles. Papers, record 42974396. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42974396

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Identification of B-cell maturation antigen (BCMA)-targeting peptides and selective drug delivery to multiple myeloma using peptide-targeted DM1 prodrug-loaded nanoparticles.
Journal
Nanoscale Adv
Year
2026
Publication types
Journal Article
Revised in PubMed
2026-11-05

Source PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Hwang GGyoyeonhttps://orcid.org/0000-0002-3335-1136
2Sobetski RHRaeleen H
3Karakus DEDoga E
4Bromley EKEmily Khttps://orcid.org/0000-0002-7160-7323
5Bilgicer BBasarhttps://orcid.org/0000-0002-4134-2547

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References37

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
138072962BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma.Blood Cancer J2023https://conductscience.org/library/papers/38072962PubMed
235661166Teclistamab in Relapsed or Refractory Multiple Myeloma.N Engl J Med2022https://conductscience.org/library/papers/35661166PubMed
327127303APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.Blood2016https://conductscience.org/library/papers/27127303PubMed
431473250Optimizing design parameters of a peptide targeted liposomal nanoparticle in an in vivo multiple myeloma disease model after initial evaluation in vitro.J Control Release2019https://conductscience.org/library/papers/31473250PubMed
523237506Regulatory roles of the tumor necrosis factor receptor BCMA.Crit Rev Immunol2012https://conductscience.org/library/papers/23237506PubMed
623841107Functionalized liposome purification via Liposome Extruder Purification (LEP).Analyst2013https://conductscience.org/library/papers/23841107PubMed
733138841In vivo evaluation of CD38 and CD138 as targets for nanoparticle-based drug delivery in multiple myeloma.J Hematol Oncol2020https://conductscience.org/library/papers/33138841PubMed
837313276Management of Ocular Toxicity in Patients Receiving Belantamab Mafodotin.J Adv Pract Oncol2023https://conductscience.org/library/papers/37313276PubMed
932276005Engineering peptide-targeted liposomal nanoparticles optimized for improved selectivity for HER2-positive breast cancer cells to achieve enhanced in vivo efficacy.J Control Release2020https://conductscience.org/library/papers/32276005PubMed
1037582952Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.Nat Med2023https://conductscience.org/library/papers/37582952PubMed
1137995307Perspectives on the Treatment of Multiple Myeloma.Oncologist2024https://conductscience.org/library/papers/37995307PubMed
1231859245Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.Lancet Oncol2020https://conductscience.org/library/papers/31859245PubMed
1322829966Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivo.Blood Cancer J2012https://conductscience.org/library/papers/22829966PubMed
1438943315Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management.Am J Hematol2024https://conductscience.org/library/papers/38943315PubMed
1525953704Potent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma.Mol Oncol2015https://conductscience.org/library/papers/25953704PubMed
1625128717Nanoparticle multivalency counterbalances the ligand affinity loss upon PEGylation.J Control Release2014https://conductscience.org/library/papers/25128717PubMed
1738961036Multiple myeloma: signaling pathways and targeted therapy.Mol Biomed2024https://conductscience.org/library/papers/38961036PubMed
1837075614Anti-BCMA surface engineered biomimetic photothermal nanomissile enhances multiple myeloma cell apoptosis and overcomes the disturbance of NF-κB signaling in vivo.Biomaterials2023https://conductscience.org/library/papers/37075614PubMed
1938961233Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins.Nat Rev Clin Oncol2024https://conductscience.org/library/papers/38961233PubMed
2037793771
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.
Lancet Haematol2023https://conductscience.org/library/papers/37793771PubMed

See all 37 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42974396

GET https://conductscience.org/api/papers/v1/42974396/references?page=2